2024 年至 2031 年胎牛血清市场规模（按应用程式、最终用户和地区划分）

胎牛血清市场评估，2024-2031

对胎牛血清（FBS）的需求不断增加，大大推动了市场的成长。人们普遍认为，FBS 在支持对于生物製药开发和疫苗生产至关重要的细胞培养和组织工程应用方面发挥着重要作用。由于需求激增，预计 2024 年市场规模将超过 9.4449 亿美元，到 2031 年将达到 213.748 亿美元。

FBS 也因其丰富的营养成分而受到重视，能够促进细胞生长和增殖，使其成为实验室和研究机构的热门选择。它在再生医学和个人化治疗中的重要性进一步促进了其用途的不断增加。预计 2024 年至 2031 年期间胎牛血清市场将以 5.30% 的复合年增长率成长。

胎牛血清市场定义/概论

胎牛血清是从胎牛血液中获得的营养丰富的产品，常用于生物技术和药物研究。它在细胞培养应用中发挥重要作用，因为它富含细胞生长和维持所需的必需营养素、生长因子和荷尔蒙。 FBS 广泛用于生物製药製造，用于开发疫苗、重组蛋白和单株抗体。它对于癌症研究、基因工程、组织工程、干细胞研究等领域的研究和开发也至关重要。

受製药和生技产业需求不断增长的推动，胎牛血清的前景看好。道德问题、供应链限制以及对开发无血清或合成血清替代品的日益关注可能会影响其发展轨迹。随着产业的发展，无动物细胞培养基的采用正在获得发展势头，这可能会从长远来看减少对 FBS 的依赖。

干细胞和再生医学研究的发展将如何推动胎牛血清的需求？

根据美国药品研究与製造商协会（PhRMA）预测，2021年生物製药业将在研发上投资约1,023亿美元，较2020年成长7.4%。这种增长直接影响对细胞培养基和补充剂（如FBS）的需求。由于胎牛血清 (FBS) 在细胞培养和组织工程中的重要作用，干细胞和再生医学研究的成长极大地推动了对胎牛血清 (FBS) 的需求。 FBS 富含必需营养素、生长因子和激素，使其成为实验室中支持干细胞生长、分化和增殖的理想培养基。在旨在修復或替换受损组织和器官的再生医学中，FBS 被广泛用于培养干细胞以用于研究和治疗应用。

人们越来越关注开发帕金森氏症、阿兹海默症和心血管疾病等退化性疾病的新疗法，这促使对 FBS 等高品质细胞培养基的需求增加。此外，随着研究人员致力于提高干细胞疗法的效率和安全性，对可靠且稳定的 FBS 来源的需求正在激增。随着再生医学领域的不断扩大，人们对 FBS 能够提供细胞生长和创新最佳环境的信任也在增加，从而促进了整个 FBS 市场的成长。

关于使用胎牛血清 (FBS) 的伦理问题将如何影响其需求和未来的市场成长？

由于胎牛血清 (FBS) 的萃取方法需要从胎牛身上抽取血液，因此关于使用胎牛血清 (FBS) 的伦理问题严重影响了其需求和市场成长。许多动物福利团体和研究人员对使用FBS提出了道德上的反对，认为它会对动物造成不必要的伤害。这促使製药和生物技术公司面临越来越大的压力，要求他们采用更人道的细胞培养替代品，例如合成培养基或植物培养基。

随着全球道德意识的增强，研究机构和公司正在探索替代方法，包括无动物培养基，以避免此类争议。此外，一些地区对动物源产品的使用实施了更严格的规定，这增加了依赖 FBS 的公司的合规复杂性。这场伦理争论不仅促使许多研究人员转向更永续的方法，而且还引发了可以为细胞提供类似生长条件的合成替代品的开发。因此，这些担忧可能会减缓未来 FBS 市场的成长，迫使公司采用创新的替代解决方案。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章胎牛血清市场（依应用）

• 生物製药业
• 学术和研究设施
• 细胞治疗与组织工程

第 5 章胎牛血清市场（依最终用户划分）

• 贸易公司
• 合约研究组织 (CRO)
• 学术和研究设施

第6章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 7 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 8 章 竞争格局

• 大型公司
• 市占率分析

第9章 公司简介

• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• RMBIO

第10章 市场展望及机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 11 章 市场展望 附录

• 缩写列表
• 来源与参考文献

Fetal Bovine Serum Market Valuation - 2024-2031

The increasing demand for fetal bovine serum (FBS) has significantly propelled the market's growth. FBS is widely recognized for its essential role in supporting cell culture and tissue engineering applications, which are crucial for biopharmaceutical development and vaccine production. This surge in demand has led to the market size exceeding USD 944.49 Million in 2024, with projections indicating it could reach a valuation of USD 21374.8 Million by 2031.

FBS is also valued for its rich nutrient composition, which enhances cell growth and proliferation, making it a preferred choice in laboratories and research institutions. Its importance in regenerative medicine and personalized therapy further contributes to its rising usage. The fetal bovine serum market is expected to grow at a compound annual growth rate (CAGR) of 5.30% from 2024 to 2031.

Fetal Bovine Serum Market: Definition/ Overview

Fetal Bovine Serum is a nutrient-rich byproduct derived from the blood of cow fetuses, commonly used in biotechnology and pharmaceutical research. It plays a critical role in cell culture applications due to its high content of essential nutrients, growth factors, and hormones needed for cell growth and maintenance. FBS is widely utilized in biopharmaceutical production for the development of vaccines, recombinant proteins, and monoclonal antibodies. It is vital in research and development for cancer research, genetic engineering, tissue engineering, and stem cell studies.

The future of the Fetal Bovine Serum looks promising, driven by increasing demand from the pharmaceutical and biotech industries. Ethical concerns, supply chain constraints, and the rising focus on developing serum-free or synthetic alternatives may shape its trajectory. As the industry evolves, the adoption of animal-free cell culture media is gaining momentum, potentially decreasing reliance on FBS in the long run.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Does the Growth in Stem Cell and Regenerative Medicine Research Drive the Demand for Fetal Bovine Serum?

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry invested approximately $102.3 billion in R&D in 2021, marking a 7.4% increase from 2020. This growth directly impacts the demand for cell culture media and supplements like FBS. The growth in stem cell and regenerative medicine research significantly drives the demand for fetal bovine serum (FBS) due to its critical role in cell culture and tissue engineering. FBS is rich in essential nutrients, growth factors, and hormones, making it an ideal medium for supporting the growth, differentiation, and proliferation of stem cells in laboratory settings. In regenerative medicine, where the goal is to repair or replace damaged tissues and organs, FBS is extensively used to culture stem cells for research and therapeutic applications.

The increasing focus on developing novel therapies for degenerative diseases, such as Parkinson's, Alzheimer's, and cardiovascular conditions, has heightened the need for high-quality cell culture media like FBS. Additionally, as researchers work on improving the efficiency and safety of stem cell therapies, the demand for reliable and consistent sources of FBS has surged. As the field of regenerative medicine expands, so does the reliance on FBS to provide an optimal environment for cell growth and innovation, thereby contributing to the overall growth of the FBS market.

How Do Ethical Concerns Regarding the Use of Fetal Bovine Serum (FBS) Impact Its Demand and Future Market Growth?

Ethical concerns regarding the use of fetal bovine serum (FBS) significantly impact its demand and market growth due to the method of its extraction, which involves harvesting blood from bovine fetuses. Many animal rights organizations and researchers have raised ethical objections to the practice, arguing that it causes unnecessary harm to animals. This has led to growing pressure on pharmaceutical and biotechnology companies to adopt more humane alternatives for cell culture, such as synthetic or plant-based media.

As ethical awareness increases globally, research institutions and businesses are exploring alternative methods, including animal-free media, to avoid these controversies. Furthermore, some regions have imposed stricter regulations on the use of animal-derived products, increasing the complexity of compliance for companies relying on FBS. This ethical debate has not only prompted many researchers to shift toward more sustainable practices but has also triggered the development of synthetic alternatives that can provide similar growth conditions for cells. As a result, these concerns are likely to slow the growth of the FBS market in the future, pushing companies to innovate and adopt alternative solutions.

Category-wise Acumens

What Factors are Driving the Increasing Demand for Fetal Bovine Serum in Academic & Research Facilities Segment?

The academic & research facilities significant stand out as a significant segment in the Fetal Bovine Serum (FBS) market, driven by the growing demand for high-quality serum in various scientific studies. FBS is widely used in cell culture applications, playing a crucial role in the growth and maintenance of cells in research involving immunology, cancer, drug development, and toxicology. The increasing focus on advancements in life sciences research, particularly in areas like stem cell research and biotechnology, has fueled the demand for FBS in academic institutions and research laboratories.

The research facilities rely on FBS for its high content of growth factors, which are essential for supporting cell viability in experimental settings. The rising number of clinical trials, coupled with the need for reliable serum to maintain reproducibility in experiments, contributes to the growth of this segment. As academic and research institutions continue to push the boundaries of scientific discovery, the demand for FBS is expected to remain strong, positioning Academic & Research Facilities as a key segment in the FBS market.

How Do Contract Research Organizations (Cros) Contribute to the Growth of the Fetal Bovine Serum Market?

The contract research organizations (CROs) segment stands out as a significant segment in the Fetal Bovine Serum (FBS) market, contributing to its growth by providing essential services such as clinical trials, product testing, and drug development. CROs play a vital role in the biotechnology and pharmaceutical industries by outsourcing research and development processes, which helps companies expedite their innovation pipelines. Their involvement in cell culture studies, vaccine development, and stem cell research drives the demand for high-quality FBS, which is essential for these applications.

The reliance on CROs for conducting large-scale clinical trials and regulatory testing is especially prominent in developing markets, where companies seek to minimize costs and access expertise in specialized areas. As the demand for biopharmaceutical products and regenerative medicine continues to rise, CROs' need for reliable, consistent sources of FBS grows in parallel. This segment's expanding role, particularly in preclinical and clinical research, further solidifies CROs' contribution to the overall growth of the FBS market, making them a key driver of its ongoing development.

Fetal Bovine Serum

Market Report Methodology

Country/Region-wise Acumens

What Are the Key Factors Driving the Growth of the Fetal Bovine Serum (FBS) Market in the North American region?

North America significantly dominates the fetal bovine serum market and is expected to maintain this position throughout the forecast period, driven by a robust biopharmaceutical industry and extensive research activities in academic and research facilities. The FDA approved 22 cell and gene therapy products as of 2023, with over 1,000 active Investigational New Drug (IND) applications for ongoing clinical studies in cell and gene therapies. The American Society of Gene & Cell Therapy reports that the number of clinical trials utilizing cell and gene therapies has grown by an average of 32% annually since 2016. The region is home to numerous biotechnology and pharmaceutical companies that utilize FBS in the production of vaccines, therapeutic proteins, and various cell culture applications, significantly boosting demand.

The increasing investment in research and development within the academic sector, along with collaborations between universities and commercial firms, further propels the growth of the FBS market. The growing trend of cell therapy and tissue engineering, where FBS is often used as a supplement in cell culture, adds to the market dynamics. Moreover, stringent quality standards and regulations in North America ensure high-quality products, reinforcing consumer trust. The emphasis on innovation and the development of advanced technologies in the biopharmaceutical field, coupled with the increasing prevalence of chronic diseases, are expected to further fuel the demand for FBS in the region, solidifying its market dominance.

How Is the Increasing Demand for Advanced Research In the Asia-Pacific Region Influencing The Fetal Bovine Serum (FBS) Market?

The Asia-Pacific region is anticipated to experience the fastest growth in the Fetal Bovine Serum (FBS), driven by the increasing demand for advanced research and therapeutic applications in various medical fields. As countries like China, Japan, and India invest significantly in healthcare infrastructure and biotechnology research, the need for effective and innovative treatment options is rising. Cryotherapy, recognized for its efficacy in pain management, muscle recovery, and rehabilitation, aligns perfectly with this growing focus on cutting-edge medical solutions.

The region is witnessing a surge in health consciousness among its population, prompting a rise in demand for non-invasive therapies. This trend is further supported by an increase in fitness and wellness facilities that utilize cryotherapy as part of their recovery programs. Moreover, favorable government policies promoting healthcare advancements and investments in medical technologies are expected to fuel market growth. The combination of growing awareness, rising healthcare expenditures, and a robust research environment position the Asia-Pacific region as a key player in the global cryotherapy market, promising a prosperous future for cryotherapy technologies and services.

Competitive Landscape

The competitive landscape of the Fetal Bovine Serum Market is dynamic and constantly evolving. New players are entering the market, and existing players are investing in research and development to maintain their competitive edge. The market is characterized by intense competition, rapid technological advancements, and a growing demand for innovative and efficient solutions.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the fetal bovine serum market include:

• Thermo Fisher Scientific
• Merck KGaA
• AGE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• MBIO
• Fetal Bovine Serum Latest Developments
• In January 2024, PixelRo, a spin-off from Samsung Electronics' internal venture fostering program C Lab, will prepare for the CES 2024. At the occasion, the company intends to reveal its groundbreaking innovations that are transforming the digital eye care industry.
• In January 2024, Aleph Farms, an Israeli meat manufacturer, reached a historic milestone when it received the world's first regulatory certification for cell-cultured beef. This accomplishment signifies a watershed moment in the alternative protein industry.
• In August 2023, Omeat, a pioneering cultured meat company that emerged from stealth mode, will reveal its unique and slaughter-free approach to the public. Currently, it is one of the first revenue-generating cultured meat firms.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Fetal Bovine Serum Market, By Application

• Biopharmaceutical Industry
• Academic & Research Facilities
• Cell Therapy & Tissue Engineering

5. Fetal Bovine Serum Market, By End User

• Commercial firms
• Contract Research Organizations (CROs)
• Academic & Research Facilities

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Atlanta Biologicals
• Bovogen Biologicals
• PAN-Biotech
• Biological Industries
• Corning Life Sciences
• Wisent Inc.
• RMBIO

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References